ALK and neuroblastoma: Despite an objective tumor response rate of 67% in children with other tumors with ALK mutations, only 1 of 11 children with neuroblastoma with ALK mutations (9%) demonstrated an objective response, suggesting that ALK inhibitors will likely need to be combined with other therapies for maximal benefit.